Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19856151 | 0.97 | FFAR4 (0.31) | ESR2DGAT1FFAR4SOAT1P2RY14 | |
| SCHEMBL19854411 | 0.95 | ESR2 (0.33) | ESR2DGAT1FFAR4SOAT1P2RY14 | |
| SCHEMBL20313627 | 0.89 | CYP2C9 (0.36) | DGAT1SOAT1P2RY14 | |
| SCHEMBL19855961 | 0.89 | DGAT1 (0.34) | ESR2DGAT1FFAR4SOAT1P2RY14 | |
| SCHEMBL19854205 | 0.88 | FFAR4 (0.32) | ESR2DGAT1FFAR4SOAT1 | |
| SCHEMBL19855363 | 0.88 | MGAT2 (0.34) | ESR2DGAT1FFAR4SOAT1P2RY14 | |
| SCHEMBL20313628 | 0.87 | CYP2C9 (0.35) | DGAT1SOAT1P2RY14 | |
| SCHEMBL19854217 | 0.85 | DGAT1 (0.32) | ESR2DGAT1FFAR4SOAT1 | |
| SCHEMBL19855089 | 0.85 | ESR2 (0.32) | ESR2DGAT1FFAR4SOAT1MGAT2 | |
| SCHEMBL20322671 | 0.85 | ESR2 (0.32) | ESR2DGAT1FFAR4SOAT1MGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| EP-3351525-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-28 | — | — | US | disclosed |
| WO-2018025974-A1 | LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE | JNC株式会社 | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | C1S, CCND1, C5 | ESR2 1953/4885DGAT1 2150/4885FFAR4 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.